Lupin gets USFDA nod for generic version of Clobex lotion
New Delhi: Drug maker Lupin said it has received approval from the US health regulator to market anti-inflammatory Clobetasol Propionate lotion in the American market.
The Mumbai-based firm said in a statement that it has received final approval for its product from the US Food and Drug Administration (USFDA).
The company's product is a generic version of Galderma Laboratories' Clobex Lotion, which is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
As per IMS MAT June data, Clobex had sales of USD 14.3 million in the US market.
American market Anti Inflammatory aprroval Clobetasol Propionate lotion Clobex lotion corticosteroid-responsive dermatoses Galderma Laboratories generic version inflammatory Lupin market pruritic manifestations USFDASource : PTI